...mechanisms of immune system responses to cancer were understood (see "ProstVac in Time," page 8). Therion Biologics Corp....
...antigen. James Breitmeyer, EVP and president of cancer immunotherapy at Bavarian Nordic, said early on Therion...
...Bavarian Nordic licensed the candidate from NCI after its original developer, Therion Biologics Corp. , went bankrupt. Therion...

...including bladder cancer, from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....

...from the National Cancer Institute (NCI), which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....

...that is active in multiple parts of the world where different HIV clades are prevalent. Therion Biologics Corp....

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....

...cancer, with data expected in 1H12. NCI regained rights to CVAC-301 after the previous licensee, Therion Biologics Corp....

...National Cancer Institute. Rights to ProstVac reverted back to the institute after the previous licensee, Therion Biologics Corp....

...being developed under a CRADA with Bavarian Nordic A/S , was originally in development at Therion Biologics Corp....
...to it," noted Thomas Schuetz, an entrepreneur-in-residence at OrbiMed Advisors, who was previously CSO at Therion...